Sensyne Health signs research agreement with NHS Trust to improve patient care and discover new treatments
Clinical artificial intelligence technology company Sensyne Health has announced that it has signed a Strategic Research Agreement (SRA) with George Eliot Hospital NHS Trust.
The agreement will allow Sensyne Health to analyse anonymised patient data using clinical AI technology. The purpose of the research is to gather new insights to improve the care of NHS Trust patients and help to find new treatments. The data for analysis will cover 746,000 hospital admissions from around 300,000 patients.
In addition, the Trust will receive a £2.5 million equity stake in Sensyne Health and will also get royalties that arise from any discoveries. The royalties the Trust receives will be reinvested back into the NHS in a bid to fund further research and deliver higher quality patient care at a lower cost.
George Eliot Hospital NHS Trust joins existing SRAs that Sensyne Health has in place with South Warwickshire Hospital, Oxford University Hospitals and Chelsea & Westminster Hospital.
According to Sensyne Health, the new SRA demonstrates that the company can develop partnerships across the whole NHS.
The research will be undertaken in accordance with information governance, data security, NHS principles and data protection legislation.
Lord Paul Drayson, CEO of Sensyne Health, commented: “We are delighted that the George Eliot Hospital NHS Trust has joined our research partnership in Clinical AI alongside South Warwickshire, Oxford University Hospitals and Chelsea and Westminster NHS Trusts. Together, we aim to make new discoveries that will improve care for patients, accelerate medical research and provide a return back into the NHS.”
Sensyne Health is a healthcare technology company that aims to discover and develop new medicines. It also strives to improve patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts.